BAYER AG
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT03411980
- Locations
- πΊπΈ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Carcinoma, Transitional Cell
- Interventions
- Drug: Rogaratinib (BAY1163877)Drug: Chemotherapy
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 175
- Registration Number
- NCT03410693
- Locations
- πΊπΈ
Summit Cancer Center, Spokane, Washington, United States
π¨π¦Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada
π¨π³Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China
- Conditions
- Pulmonary Embolism
- Interventions
- Drug: Rivaroxaban(Xarelto, BAY 59-7939)
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 288
- Registration Number
- NCT03410706
- Locations
- π¨π³
Many locations, Multiple Locations, China
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 120
- Registration Number
- NCT03408093
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
- Conditions
- Hemophilia A
- Interventions
- Drug: FVIII productsDrug: Conventional FVIII replacement therapies
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 160
- Registration Number
- NCT03405337
- Locations
- πΊπΈ
Many Locations, Whippany, New Jersey, United States
A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 387
- Registration Number
- NCT03404206
- Locations
- πΊπΈ
Jean Brown Research, Salt Lake City, Utah, United States
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
- Conditions
- Leukemia
- Interventions
- Drug: BAY2402234
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT03404726
- Locations
- πΊπΈ
Vanderbilt University Medical Center, Nashville, Tennessee, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
π«π·Institut Gustave Roussy, Villejuif Cedex, France
Renal Impairment Study
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT03402438
- Locations
- π©πͺ
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT03400956
- Locations
- πΊπ¦
Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine
π―π΅Matsudo City General Hospital, Matsudo, Chiba, Japan
π―π΅Tokeidai Memorial Clinic, Sapporo, Hokkaido, Japan
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 93
- Registration Number
- NCT03400943
- Locations
- πΊπΈ
South Florida Medical Research, Aventura, Florida, United States
πΊπΈChattanooga Medical Research, LLC, Chattanooga, Tennessee, United States
πΊπΈSweet Hope Research Specialty, Inc. - Hialeah, Hialeah, Florida, United States